Vertex Pharmaceuticals Incorporated
VRTX
$448.29
$13.123.02%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.03B | 1.19B | 1.08B | 1.03B | 646.30M |
| Total Depreciation and Amortization | 55.90M | 24.50M | 54.00M | 51.70M | 48.40M |
| Total Amortization of Deferred Charges | -- | 31.20M | -- | -- | -- |
| Total Other Non-Cash Items | 96.10M | 199.00M | -45.10M | 120.90M | 392.70M |
| Change in Net Operating Assets | 244.70M | -947.80M | 149.60M | -132.40M | -268.50M |
| Cash from Operations | 1.43B | 498.00M | 1.24B | 1.07B | 818.90M |
| Capital Expenditure | -133.40M | -149.40M | -101.80M | -145.70M | -40.70M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -298.50M | -138.70M | -15.20M | -338.80M | -15.10M |
| Cash from Investing | -431.90M | -288.10M | -117.00M | -484.50M | -55.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -1.40M | -1.40M | -1.30M | -- |
| Issuance of Common Stock | 27.00M | 54.00M | 7.90M | 49.10M | 16.70M |
| Repurchase of Common Stock | -565.40M | -130.90M | -1.16B | -397.70M | -696.60M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -400.00K | 1.10M | 1.10M | 700.00K | -500.00K |
| Cash from Financing | -538.80M | -77.20M | -1.15B | -349.20M | -680.40M |
| Foreign Exchange rate Adjustments | -40.30M | 7.30M | -4.10M | 57.20M | 30.50M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 417.10M | 140.00M | -34.20M | 296.60M | 113.20M |